Trump Administration Ends Medicare Part D Subsidy Program

The Trump administration announced this week that it will terminate a subsidy program that has helped to maintain lower and more stable Medicare Part D premiums. This program, which has been in effect since 2006, provides prescription drug coverage for Medicare beneficiaries. The Biden administration had previously enhanced the program in 2022 through the Inflation Reduction Act, introducing an out-of-pocket spending cap, enabling price negotiations for certain drugs, and establishing a monthly cap on insulin costs. However, the Trump administration's decision will see the end of these additional subsidies in 2027.

The precise number of seniors who may face increased prescription drug expenses and the magnitude of these potential cost hikes remain unclear. Juliette Cubanski, vice president and director of KFF’s Program on Medicare Policy, stated that without these subsidies in place for 2027, some enrollees in stand-alone Part D drug plans could experience larger premium increases for their drug coverage. Data from MedPAC indicates that the premium subsidies provided under the program were projected to reduce the average cost of prescription drug premiums by $26 in 2025 and $16 in 2026. Enrollment in the Medicare Part D program has seen growth, increasing from 22.6 million beneficiaries in 2024 to an estimated 24.9 million in 2026, according to KFF. Despite these subsidies, the average monthly price for prescription drug premiums in 2026 is projected to be more than four times higher than the average premium for drug coverage offered within Medicare Advantage plans.

The rationale behind this policy change stems from concerns regarding the program's overall cost. The total expenditure for the subsidy program was estimated at $9.8 billion for the years 2025 and 2026. Dr. Mehmet Oz, administrator of the Centers for Medicare and Medicaid Services (CMS), communicated this decision via a statement on X, citing the program's financial implications as a key factor in the administration's decision to discontinue the subsidies. The termination of these subsidies is expected to shift a greater portion of the premium costs directly onto beneficiaries, potentially impacting their ability to afford necessary medications. This move reverses a trend of expanding prescription drug affordability measures implemented in recent years, raising questions about the future accessibility and cost of prescription drugs for a significant segment of the elderly population. The Centers for Medicare and Medicaid Services (CMS) oversees the Medicare program, which is a federal health insurance program primarily for people aged 65 or older, as well as for some younger people with disabilities and End-Stage Renal Disease. Medicare Part D specifically addresses prescription drug coverage, a critical component of healthcare for many seniors who often manage multiple chronic conditions requiring ongoing medication.

The discontinuation of the Medicare Part D subsidy program represents a significant policy shift that could have far-reaching consequences for millions of Americans. The program's original intent was to alleviate the financial burden of prescription drugs, a cost that can be prohibitive for many individuals, particularly those on fixed incomes. The Inflation Reduction Act's provisions, such as the out-of-pocket cap, aimed to provide further financial relief and predictability for beneficiaries. By removing these subsidies, the Trump administration is signaling a different approach to managing the costs associated with Medicare Part D, prioritizing fiscal considerations over the direct subsidization of premiums. This decision is likely to be closely watched by patient advocacy groups, pharmaceutical companies, and healthcare policy experts as the full impact on drug affordability becomes apparent in the coming years. The projected increases in premiums, even if seemingly small on a per-beneficiary basis, could accumulate into substantial additional expenses for millions of individuals relying on Medicare for their healthcare needs.